Free Trial

Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

$8.67
+0.23 (+2.73%)
(As of 11:10 AM ET)

Iovance Biotherapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$24.45
182.06% Upside
High Forecast$34.00
Average Forecast$24.45
Low Forecast$17.00
TypeCurrent Forecast
7/13/23 to 7/12/24
1 Month Ago
6/13/23 to 6/12/24
3 Months Ago
4/14/23 to 4/13/24
1 Year Ago
7/13/22 to 7/13/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.45$24.64$24.64$19.09
Forecasted Upside182.06% Upside117.01% Upside104.51% Upside153.74% Upside
Get Iovance Biotherapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

IOVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IOVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Iovance Biotherapeutics Stock vs. The Competition

TypeIovance BiotherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside189.75% Upside959.42% Upside10.19% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00+293.12%
6/20/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $23.00+187.50%
3/14/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$18.00 ➝ $19.00+31.85%
3/1/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$22.00 ➝ $25.00+57.13%
2/29/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$19.00 ➝ $21.00+26.43%
2/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$18.00 ➝ $22.00+26.22%
2/20/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$29.00 ➝ $34.00+271.58%
12/27/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$17.00+91.23%
9/15/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$30.00+445.45%
9/13/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$27.00 ➝ $26.00+342.93%
8/9/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$23.00 ➝ $20.00+180.11%
3/1/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$25.00 ➝ $15.00+105.76%
12/9/2022Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral$20.00 ➝ $6.00-7.83%
10/31/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:29 AM ET.

IOVA Forecast - Frequently Asked Questions

What is Iovance Biotherapeutics' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Iovance Biotherapeutics is $24.45, with a high forecast of $34.00 and a low forecast of $17.00.

Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.

Does Iovance Biotherapeutics's stock price have much upside?

According to analysts, Iovance Biotherapeutics's stock has a predicted upside of 126.27% based on their 12-month stock forecasts.

What analysts cover Iovance Biotherapeutics?

Iovance Biotherapeutics has been rated by research analysts at HC Wainwright, and JMP Securities in the past 90 days.

Do Wall Street analysts like Iovance Biotherapeutics more than its competitors?

Analysts like Iovance Biotherapeutics more than other "medical" companies. The consensus rating for Iovance Biotherapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IOVA compares to other companies.


This page (NASDAQ:IOVA) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners